<DOC>
	<DOCNO>NCT00004314</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine effect aminoimidazole carboxamide riboside ( AICAR ) hematologic manifestation Lesch-Nyhan disease . II . Assess behavioral neurological benefit AICAR patient Lesch-Nyhan disease . III . Examine effect AICAR purine production .</brief_summary>
	<brief_title>Phase II Pilot Study Aminoimidazole Carboxamide Riboside ( AICAR ) , Precursor Purine Synthesis , Lesch-Nyhan Disease</brief_title>
	<detailed_description>PROTOCOL OUTLINE : After 3-day baseline , patient treat aminoimidazole carboxamide riboside ( AICAR ) continuous infusion 12 day . Concurrent allopurinol folate allow .</detailed_description>
	<mesh_term>Lesch-Nyhan Syndrome</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Men LeschNyhan syndrome Moderate erythrocyte macrocytosis No active urinary tract disease impair renal function</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2000</verification_date>
	<keyword>Lesch-Nyhan syndrome</keyword>
	<keyword>inborn error metabolism</keyword>
	<keyword>neurologic psychiatric disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>